ERBB2 and cancer: In four molecular subtypes, HER2-positive (HR-negative) and TNBC subtype showed higher prediction scores than HER2-positive (HR-positive) and Luminal (A/B) subtype, implying different cancer subtypes response differently to chemotherapy, which was consistent with previous studies (2, 5, 9).